Equidyne upbraids Rosch for INJEX claims:
This article was originally published in Clinica
Executive Summary
Equidyne of San Diego, US, has responded to an announcement by Rosch Medizintechnik (Frankfurt, Germany) regarding the INJEX reusable needle-free injection system. Rosch said that it had received US FDA 510(k) approval for the system and would be able to market it in the US. Equidyne says that it owns all US patents covering the INJEX technology and that Rosch, which has European marketing rights, has no US marketing rights other than for INJEX growth hormone. Rosch, which was spun out of Equidyne in 2000, sold exclusive worldwide distribution rights to INJEX for the delivery of hormone deficiency products to an unnamed pharmaceutical company in March, which entailed a $254,000 payment to Equidyne.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.